



Thursday, November 7, 2019

07:30 *Registration*

08:30 - 09:30 UVEITIS
Chair: **Ron Neumann**, Israel

Long Term systemic effects of Immunosuppressive drugs

08:30 Steroids
Francine Behar-Cohen, France

08:35 TNF inhibitors
Alfredo Adan, Spain

08:40 Methotrexate
William Ayliffe, UK

08:45 Mycophenolate mofetil
Marc de Smet, Switzerland

Discussion
Session Speakers
Moderator: **Ron Neumann**, Israel

08:50 Total burden on health of systemic therapy
Topical/systemic drugs decision making
Allowing development of cataract vs. long term effects of systemic
The art of discontinuing systemic therapy
Vaccinations and epidemics in modern times and the immunosuppressed patient

09:30 *Coffee Break*

10:00 - 11:00 KEYNOTE LECTURE & FREE PAPERS

10:00 *Keynote Lecture:*
Lessons Learned in Ophthalmic Biotech as a CEO, Venture Capitalist and Clinician
David Guyer, USA

10:15 Free Papers
TBA



Thursday, November 7, 2019 (Continued)

11:00 - 12:00 **ENDOPHTHALMITIS**
Chair: **Irina Barequet**, Israel

- 11:00 Intraocular Drug-related Complications of Endophthalmitis Prophylaxis
Tat Keong Chan, Singapore
- 11:10 The effect of recurrent povidone-iodine usage on conjunctival flora in diabetic patients undergoing Intravitreal Injections
Adi Einan Lifshitz, Israel
- 11:20 Diagnostic vitrectomy for suspect endophthalmitis
Anat Loewenstein, Israel
- 11:30 LasA Protease and an adjunct enzyme-based therapy for endophthalmitis
Irina Barequet, Israel
- 11:40 Debate: antibiotics for intraocular infections: Yes or NO?
Anat Loewenstein, Israel

12:00 *Lunch Break*

13:00 - 15:00 **MANAGEMENT OF AMD**

13:00 - 14:30 **PART 1: IMAGING AND MANAGEMENT IN AMD**
Chairs: **Karina Berg**, Norway & **Paolo Lanzetta**, Italy

- A. IMAGING: DIAGNOSIS AND FOLLOW UP**
- 13:00 OCT angiography biomarkers in neovascular AMD
Luis Arias Barquet, Spain
- 13:05 Imaging in dry AMD
Alfredo Garcia-Layana, Spain
- 13:10 Non-exudative CNV; To treat or not?
Paolo Lanzetta, Italy
- 13:15 Hyper-reflective foci in AMD
Francesco Bandello, Italy
- Discussion**
- 13:20 When should we diagnose and treat? Prior to clinical finding?
Current practice and role of imaging in AMD
Indications for Fluorescein/Indocyanin Green



Thursday, November 7, 2019 (Continued)

13:00 - 14:30 PART 1 (Continued)

B. TREATMENT

- 13:40 Management of polypoidal lesions (Atlantic study)
Rufino Silva, Portugal
- 13:45 Key points of RIVAL study
Karina Berg, Norway
- 13:50 Treat and Extend latest evidence with aflibercept (ALTAIR study)
Stela Vujosevic, Italy
- 13:55 Retreatment criteria for AMD (FLUID study)
TBA

Discussion

Does the régime matter?

- 14:00 Management of bilateral wet AMD
Evidence or lack of it for ideal regimen
Evidence for TAE, addressing deteriorating lesions
Repeat loading dose Vs. Revert to Previous step?
Guidance to discontinue treatment; The role of visual acuity
-



Thursday, November 7, 2019 (Continued)

14:20 - 15:00 **PART 2: THE ROLE OF NEW MOLECULES?**
Chair: **Baruch Kuppermann**, USA

- 14:20 Brolucizumab
Enrique Cervera, Spain
- 14:25 Abicipar phase III
Baruch Kuppermann, USA
- 14:30 Brimonidine tartrate in AMD
Albert Augustin, Germany
- 14:35 Update on Complement inhibition results
TBA
- Discussion**
The next strategic step: Improved delivery?
New Chemical/biological entities vs. available drugs imported from other medical fields
New non-drug strategies?
When current therapy becomes ineffective, is there a next step?
Learning from lomalizumab failure; can we learn from the dementia studies failure?

15:00 *Coffee Break*

15:30 - 17:30 **DIABETIC MACULAR EDEMA**
Chairs: **Patricia Udaondo**, Spain & **Stela Vujosevic**, Italy

IMAGING IN DME

- 15:30 Prognostic and predictive biomarkers in DME
Patricia Udaondo, Spain
- 15:35 Microvascular changes as predictor for DME progression
Maria Cristina Parravano, Italy
- 15:40 How can we define chronic DME?
Stela Vujosevic, Italy
- 15:45 Discussion



Thursday, November 7, 2019 (Continued)

15:30 - 17:30 DIABETIC MACULAR EDEMA (Continued)

DME MANAGEMENT

- 16:00 Real world evidence with fluocinolone implant in DME
Francesco Bandello, Italy
- 16:05 Long term efficacy and safety of Dexamethasone implant for DME
Alfredo Adan, Spain
- 16:10 Real life outcomes of anti-VEGF therapy in DME
Paolo Lanzetta, Italy
- 16:15 Take home messages of latest protocols of DRCR.net (T and V)
TBA
- 16:20 The EURETINA guidelines for DME
Karina Berg, Norway
- 16:25 Combined therapy in DME
Enrique Cervera, Spain
- Discussion**
Combine therapy
Loading dose
- 16:30 Treating eyes with good visual acuity
Interpretation of protocol T results
Role for surgery
- FORSEEN FUTURE IN DME**
- 16:50 Phase II trials that succeeded and fail for DME: angiopoietin vs Tie2
TBA
- 16:55 Phase I first-in-human study of KSI-301: a novel anti-VEGF antibody dimeric conjugate (ABC) with extended durability
J. Pablo Velazquez-Martin, USA
- 17:00 Drugs in pipeline for DME
Marc de Smet, Switzerland
- 17:05 Discussion
-
- 17:30 *End of Day's Sessions*
-



Friday, November 8, 2019

08:30 - 09:30 **ADVANCED AMD**
Chair: **Usha Chakravarthy**, UK

- 08:30 Review the pathogenesis of AMD and the pathways to CNV and GA
Jordi Mones, Spain
- 08:37 Discussion
- 08:45 Examine current therapeutics and consider the long-term outcomes and unmet need
Tunde Peto, UK
- 08:52 Discussion
- 09:00 Evaluate the current therapeutic pipeline critically assessing the appropriateness of targets
Usha Chakravarthy, UK
- 09:07 Discussion
- 09:15 Designing new therapies with precision medicine in mind
Anat Lowenstein, USA
- 09:22 Discussion

09:30 *Coffee Break*

10:00 - 11:00 **ARTIFICIAL INTELLIGENCE**
Chairs: **Tunde Peto**, UK & **Leopold Schmetterer**, Singapore

- 10:00 Artificial Intelligence in retinal imaging
Javier Zarranz, Spain
 - 10:15 Future in imaging. Functional Imaging
Tunde Peto, UK
 - 10:30 Artificial Intelligence for glaucoma
Leopold Schmetterer, Singapore
 - 10:45 Discussion
-



Friday, November 8, 2019 (Continued)

11:00 - 12:00 **GENE THERAPY**
Chair: **TBA**

Neurotech for CNTF in MacTel
TBA

Viral vectors for anti-VEGF in AMD
Peter Kaiser, USA

Rdcvf for neuroprotection
Thierry Léveillard, France

Eyevensys technology
Francine Behar-Cohen, France

12:00 - 13:00 **COMPANY SPONSORED LUNCH SESSION**

13:00 - 15:00 **DRUG DELIVERY**
Chairs: **Diane Tang Liu**, USA & **Uday Kompella**, USA

- 13:00 Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Agents
Arup Das, USA
- 13:10 Microspheres as therapeutic systems to treat retinal diseases
Martia Del Rocio Herrero-Varnell, Spain
- 13:20 Nanoformulation as intraocular drug delivery system to target the posterior segment
Martina Giannaccini, Italy
- 13:30 TBA
Mark Vezina, Canada
- 13:40 Targeted treatment of retinoblastoma with an oncolytic adenovirus
Angel Montero Carcaboso, Spain
- 13:50 Extended Duration Anti-VEGF therapy: the Promises and Disappointments
Michael W. Stewart, USA
- 14:00 Tunable duration of prolonged drug release from a novel formulation
Diane Tang-Liu, USA
- 14:10 Biodegradable intraocular implants
Uday Kompella, USA
- 14:20 Clearside Biomedical, Inc., VP, Discovery
Viral Kansara, USA
- 14:30 Discussion



Friday, November 8, 2019 (Continued)

15:00 *Coffee Break*

15:30 - 16:30 **CENTRAL SEROUS CHOROIDOPATHY**
Chairs: **Francine Behar-Cohen**, France & **Jose María Ruiz Moreno**, Spain

TBA

16:30 - 17:15 **RETINAL VEIN OCCLUSION**
Chairs: **Albert Augustin**, Germany & **Alfredo García-Layana**, Spain

16:30 Multimodal imaging: assessing non perfusion
Albert Augustin, Germany

16:35 The LEAVO trial
Usha Chakravarthy, UK

16:40 Long term efficacy of steroids in management of macular edema in vein Occlusion
Ibraheem El Ghrably, Abu Dhabi

16:45 Latest evidence of anti VEGF in vein occlusion
Choi-Mun Chan, Singapore

16:50 Laser in vein occlusion: when and for what?
Alfredo García-Layana, Spain

16:55 Discussion with clinical cases

17:15 *End of Day's Sessions*



Saturday, November 9, 2019

08:00 - 08:45 **INHIBITION OF DIABETIC RETINOPATHY**
Chair: **Arup Das**, USA

- 08:00 Targeting G-proteins to inhibit Diabetic Retinopathy
Renu Kowluru, USA
- 08:10 Kallikrein-Kinin System in Diabetic Retinopathy - Novel Target
Edward Feener, USA
- 08:20 Targeting IL-6 Signaling to Intervene in the Progression of Diabetic Retinopathy
Susanne Mohr, USA
- 08:30 Combotherapy of Diabetic Retinopathy: Emerging Paradigm
Ashwath Jayagopal, Switzerland

08:45 - 09:30 **THERAPY OF RETINAL ANGIOGENESIS**
Chair: **Arup Das**, USA

- 08:45 Non-coding RNA based Therapeutics
Subrata Chakarabarti, Canada
- 08:55 Control of Retinal Angiogenesis by modification of cell membrane lipid composition and membrane fluidity
Julia Busik, USA
- 09:05 Inflammation in Early Diabetic Retinopathy
John Penn, USA
- 09:15 Glial influence in the pathogenesis of Diabetic Retinopathy
Debasish Sinha, USA

09:30 *Coffee Break*



Saturday, November 9, 2019 (Continued)

10:00 - 11:00 GENE THERAPY
Chair: **Neena Haider**, USA

TBA

11:00 - 12:00 KEYNOTE LECTURE & FREE PAPERS

11:00 *Keynote Lecture:*
Down to earth: harnessing artificial intelligence to improve retinal diagnosis and health
Dimitri Azar, USA

11:15 FREE PAPERS

12:00 *Lunch Break*

13:00 - 14:00 **DIABETIC RETINOPATHY**
Chairs: **Francesco Bandello**, Italy, & **Rufino Silva**, Portugal

13:00 OCT-A in patients without diabetic retinopathy
Francesco Bandello, Italy

13:07 Comparison of FA and OCTA in DR
Luis Arias Barquet, Spain

13:14 Ultra-widefield swept source OCTA in DR
Maria Cristina Parravano, Italy

13:21 Diabetic retinopathy treated with anti-VEGF: results on clinical trials
Francesco Bandello, Italy

13:28 Update on DRCR.net studies in DR
Itay Chowers, Israel

13:35 Is it safe to space out injections when you are treating PDR with anti-VEGF alone?
Rufino Silva, Portugal

13:42 Surgery in DME. When and How?
Jose García Arumí, Spain

13:49 Discussion and clinical cases



Saturday, November 9, 2019 (Continued)

14:00 - 15:00 **MYOPIA**
Chairs: **Jose García Arumí**, Spain & **Jose Maria Ruiz-Moreno**, Spain

- 14:00 Myopic maculopathy; new classification Jose
Maria Ruiz-Moreno, Spain
- 14:07 Factors influencing visual acuity in patients receiving anti VEGF for myopic CNV
Francesco Boscia, Italy
- 14:14 Update on myopic CNV management
Choi-Mun Chan, Singapore
- 14:21 The Dome shaped macula and it's potential treatments
Itay Chowers, Israel
- 12:28 When is surgery the option in myopic maculopathy?
Jose García Arumí, Spain
- 14:35 Discussion

15:00 *Coffee Break*

15:30 - 17:00 **CHALLENGING CASES**
Chair: TBA

Free papers concerning challenging cases

17:00 *End of Day's Sessions*
